Drug Trial Radar · NCT05597917
tTF-NGR Randomized Study - STS
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Oct 26, 2021
Primary completion
Dec 2030
Study completion Jun 2031
Sponsor
- Lead sponsor
- Universität MünsterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Anturec Pharmaceuticals GmbH
- First posted
- Oct 28, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this phase III open label, controlled clinical trial patients with unresectable or metastatic soft-tissue sarcoma after failure of anthracycline-containing first line therapy or with contraindications to these drugs and CD13 positivity in central histology (grade \>/= 1+) are treated to evaluate whether tTF-NGR in combination with standard trabectedin chemotherapy prolongs progression-free survival (according to iRECIST), as compared with trabectedin alone. Further objectives are to evaluate the efficacy of tTF-NGR in combination with standard trabectedin chemotherapy with respect to the response rate and overall survival as well as to assess the safety profile of tTF-NGR combined with trabectedin. Before the randomized phase III part of the study, there was a safety run-in part. The final dose of tTF-NGR established as safe in this safety run-in part is 0.5 mg/m2 per day for 2 consecutive days following each trabectedin infusion and is used for the randomized (parallel 1:1; Arm 1: standard trabectedin, Arm 2: standard trabectedin plus tTF-NGR) phase III part of this trail. . Further dose modification for tTF-NGR is possible.
Conditions
- Soft Tissue Sarcoma
Interventions
TrabectedinDrug
Patients will receive standard trabectedin 1.5 mg/m2 as a 24-hour central intravenous (IV) infusion on day 1, q d 22 x until disease progression or contraindications against further application.
tTF-NGRBiological
Patients will receive standard trabectedin according to arm 1 plus 0.5 mg/m2 f tTF-NGR (1-hour rate-controlled infusion, port or central venous access, 0.9 % NaCl ad 100 mL) on days 2 and 3 following each trabectedin cycle (within max 2 hours interval between end of trabectedin infusion and tTF-NGR: e.g.: trabectedin on monday 8 am to tuesday 8 am followed by tTF-NGR on tuesday 10 am and on the following day, q d 22 x until disease progression or contraindications against further application. Further dose modification for tTF-NGR is possible (see chapter 6.1.4 of the protocol).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy: Prolongation of progression-free survival (PFS) according to iRECIST as judged by central radiology in a blinded fashion after end of trial.Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Universitätsklinikum Augsburg
Augsburg, Germany · Recruiting
HELIOS Klinikum Bad Saarow
Bad Saarow, Germany · Recruiting
HELIOS Klinikum Berlin-Buch
Berlin, Germany · Recruiting
TU Dresden Medizinische Fakultät Carl Gustav Carus
Dresden, Germany · Recruiting
Universitätsklinikum Frankfurt
Frankfurt, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Medizinische Hochschule Hannover
Hanover, Germany · Recruiting
Universitätsklinikum Heidelberg
Heidelberg, Germany · Recruiting
Universitätsklinikum Jena
Jena, Germany · Recruiting
Universitätsklinikum Leipzig
Leipzig, Germany · Recruiting
Universitätsmedizin Mainz
Mainz, Germany · Recruiting
LMU Klinikum
München, Germany · Recruiting
Klinikum rechts der Isar der technischen Universität München
München, Germany · Recruiting
University Hospital Muenster, Germany
Münster, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.